PF-06873600 is a selective and orally bioavailable cyclin-dependent kinase (CDK) inhibitor(CDK2, CDK4 and CDK6 with Ki of 0.09 nM, 0.13 nM and 0.16 nM, respectively), has potential antineoplastic activity.

PF-06873600 selectively targets, binds to and inhibits the activity of CDKs.?Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation.?CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells.

2185857-97-8

C20H27F2N5O4S

471.52

PF-06873600

[1]NCI Drug Dictionary

DMSO:83.33 mg/mL (176.73 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years